Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Essilor International SA

www.essilor.com

Latest From Millenium Biologix Inc.

Takeda strengthens cancer focus with Mersana ADC deal

Takeda is ramping up its presence in oncology, having signed a deal with antibody-drug conjugate (ADC) specialist Mersana Therapeutics via subsidiary Millennium Pharmaceuticals.

Infectious Diseases Cancer

Medtronic: Ready to Deal Again

A decade ago, Medtronic shook up itself and the device industry with a series of large deals over a short period of time. In the process, the company tranformed itself from a leader in cardiac rhythm management into the industry's largest, most diversified device company. More recently, the company has been quieter, focusing on smaller deals, both acquisitions and minority investments. In But in this interview, Medtronic's head of Corporate Development, Bob White, says that Medtronic is ready to deal again and talks about the kinds of companies it's interested in.
Medical Device Business Strategies

When the Body Alone Can't Build Bone

Orthobiologics are now on the horizon, driving suppliers to increase R&D spending. The goal is to develop high-margin products that will actively promote bone formation. Has the slow progress to commercialization of the first two products--bone morphogenic proteins developed by the collaborations of Stryker Corp/Creative Biomolecules and Genetics Institute/Sofamor Danek--helped prime the market to accept a new technology? Or has the perception of delay dampened enthusiasm and scared off some of the big orthopedics players?
BioPharmaceutical Medical Device

Millenium Biologix

Biomaterials; Bone Repair. Millenium's product line consists of four major groups: an analytical kit for bone cell assays for research and clinical trials, a synthetic bone material for coating artificial joints or dental implants, a synthetic bone material that can be used as a stand-alone product or in conjunction with bone growth factors, and product which can be seeded with a patient's own bone or stem cells to grow autologous bone for grafts.
BioPharmaceutical Medical Device
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register